Bristol Myers Squibb (CELG-RI) Change in Receivables (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has 18 years of Change in Receivables data on file, last reported at -$1.7 billion in Q1 2026.

• Change in Receivables for Q1 2026 came in at -$1.7 billion, down 11146.67% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.4 billion (down 788.5% YoY), and the FY2025 annual result was $295.0 million, up 211.74% from the prior year.
• Change in Receivables slipped to -$1.7 billion in Q1 2026 per CELG-RI's latest filing, from -$19.0 million in the prior quarter.
• Over five years, Change in Receivables peaked at $1.0 billion in Q2 2024 and troughed at -$1.7 billion in Q1 2026.
• A 5-year average of $117647.1 and a median of $65.0 million in 2023 frame the typical range for Change in Receivables.
• The sharpest annual moves came in 2024 and 2026: Change in Receivables soared 1467.69% in 2024, then slumped 11146.67% in 2026.
• A 5-year view of Change in Receivables shows it stood at $106.0 million in 2022, then jumped by 379.25% to $508.0 million in 2023, then sank by 128.15% to -$143.0 million in 2024, then surged by 86.71% to -$19.0 million in 2025, then sank by 8778.95% to -$1.7 billion in 2026.
• Business Quant data shows CELG-RI's Change in Receivables at -$1.7 billion in Q1 2026, -$19.0 million in Q4 2025, and -$155.0 million in Q3 2025.